肾康注射液联合厄贝沙坦对早期糖尿病肾病患者的疗效

目的探讨肾康注射液联合厄贝沙坦治疗早期糖尿病肾病的临床效果。方法 84例早期糖尿病肾病患者作为研究对象,随机分为观察组和对照组,两组均给予常规降糖药治疗和胰岛素等其他基础治疗,对照组加用肾康注射液治疗,观察组在对照组基础上加用肾康注射液和厄贝沙坦治疗。结果两组患者均顺利完成治疗,治疗期间均未发生严重的药物不良反应。治疗后两组UAER,Cr和BUN均有显著性改善(均P<0.01),但观察组上述指标改善程度显著大于对照组(均P<0.01)。结论对于早期糖尿病肾病患者采取肾康注射液和厄贝沙坦联合用药,有效性和安全性高,值得临床考虑。

The Clinical Effect of Shenkang Injection Combined with Irbesartan Used for Patients with Diabetic Nephropathy at Early Stage

Objective To explore the clinical effect of shenkang injection combined with irbesartan used for patients with diabetic nephropathy at early stage. Methods 84 cases of patients with diabetic nephropathy at early stage as studied object were randomly divided into experimental group and control group. Two groups were given base therapy such as hypoglycemic drugs and insulin, control group was added with shenkang injection, and experimental group were added with combined with irbesartan on base of control group. Results The therapy of two groups was smooth, and there was no serious side- reaction happened during therapy stage. After therapy, the UAER, Cr and BUN in two groups were turned well significantly （all P〈0.01）, but the indexes in experimental group were turned significantly better than in control group （all P〈0.01）. Conclusion For patients with diabetic nephropathy at early stage, therapy of shenkang injection combined with irbesartan show high effectively and safety, so it deserved considering in clinical work.